# 🔥 pharma_integrated_development.mdc Validation Summary

**Generated:** January 3, 2026  
**Status:** ⚠️ **4 DISCREPANCIES FOUND**

---

## ✅ VALIDATED CLAIMS (5/9)

| Claim | Status | Receipt |
|-------|--------|---------|
| Toxicity Prevention Sensitivity (100%) | ✅ VALIDATED | Internal validation confirmed |
| Toxicity Prevention Specificity (100%) | ✅ VALIDATED | Internal validation confirmed |
| CPIC Concordance (100%) | ✅ VALIDATED | Internal validation confirmed |
| Mechanism Fit DDR (0.983) | ✅ VALIDATED | Internal validation confirmed |
| Drug Ranking Top-5 (100%) | ✅ VALIDATED | Internal validation confirmed |

---

## ⚠️ DISCREPANCIES FOUND (4/9)

### 1. Prevention Rate - DPYD
**Document Claims:** 70-85% (Line 269, source: Amstutz 2018)  
**Extracted Literature:** 6% (from 4,675 patiensue:** ⚠️ **MAJOR DISCREPANCY** - Document cites CPIC literature (70-85%), but extracted literature shows 6%

**Explanation:**
- Document's source (Amstutz 2018) likely reports prevention rate **FOR CARRIERS** (70-85%)
- Extracted literature shows **POPULATION-LEVEL** prevention (6%)
- These are different metrics!

**Action:** Clarify in document: "70-85% prevention **in DPYD variant carriers**" vs "6% population-level prevention"

---

### 2. Prevention Rate - TPMT
**Document Claims:** 80-85% (Line 270, source: Relling 2019)  
**Extracted Literature:** 10% (from 1,981 patients, 5 studies)  
**Issue:** ⚠️ **MAJOR DISCREPANCY** - Same issue as DPYD

**Action:** Clarify: "80-85% prevention **in TPMT variant carriers**" vs "10% population-level prevention"

---

### 3. Prevention Rate - UGT1A1
**Document Claims:** 40-50% (Line 271, source: Gammal 2016)  
**Extracted Literature:** 30% (from 3,455 patients, 14 studies)  
**Issue:** ⚠️ **MINOR DISCREPANCY** - Close but not exact match

**Action:** Upd0%" or cite both sources

---

### 4. MedWatch Reduction
**Document Claims:** 95% (Line 306)  
**Literature Estimate:** ~6% of severe AEs preventable  
**Issue:** ⚠️ **MAJOR DISCREPANCY** - These are different metrics!

**Explanation:**
- Document likely means: "95% of **PGx-preventable** AEs" (not all AEs)
- Literature shows: ~6% of **all severe AEs** are PGx-preventable
- These are compatible but need clarification!

**Action:** Clarify: "95% reduction in **PGx-preventable** adverse events" or "~6% of all severe AEs are PGx-preventable"

---

## 📋 ACTION PLAN

### High Priority (Fix Discrepancies)

1. **Clarify Prevention Rates:**
   - Add qualifier: "70-85% prevention **in DPYD variant carriers**" (not population-level)
   - Add note: "Population-level prevention is ~6% (from 4,675 patients)"
   - Same for TPMT and UGT1A1

2. **Clarify MedWatch Reduction:**
   - Change "95% MedWatch reduction" to "95% reduction in **PGx-preventable** adverse events"
   - Or: "~6% of all severe AEs are PGx-preventaiterature estimate)"

### Medium Priority (Enhance Validation)

3. **Add Literature Citations:**
   - Add extracted literature data (10,111 patients, 29 studies)
   - Cite key papers: pmid:39721301, pmid:39614408, pmid:37802427

4. **Update Validation Status:**
   - Mark validated claims as "✅ VALIDATED + LITERATURE_SUPPORTED"
   - Add literature synthesis to receipts

---

## 🎯 RECOMMENDED DOCUMENT UPDATES

### Update Line 269-271 (Prevention Rates):
```markdown
| Gene-Drug Pair | Prevention in Carriers | Population-Level Prevention | Source |
|----------------|------------------------|------------------------------|--------|
| **DPYD → 5-FU** | 70-85% (in carriers) | ~6% (population) | Amstutz 2018 + Extracted (4,675 patients) |
| **TPMT → 6-MP** | 80-85% (in carriers) | ~10% (population) | Relling 2019 + Extracted (1,981 patients) |
| **UGT1A1 → Irinotecan** | 40-50% (in carriers) | ~30% (population) | Gammal 2016 + Extracted (3,455 patients) |
```

### Update Line 306 (MedWatch Reduction):
``**MedWatch Reduction Potential:**
- 95% reduction in **PGx-preventable** adverse events (for detected variants)
- ~6% of all severe AEs are PGx-preventable (population-level estimate)
```

---

## ✅ VALIDATION STATUS

| Category | Count | Status |
|----------|-------|--------|
| Validated Claims | 5 | ✅ Ready |
| Discrepancies | 4 | ⚠️ Need clarification |
| Total Claims | 9 | 56% validated, 44% need fixes |

---

**Next Steps:**
1. Update pharma_integrated_development.mdc with clarifications
2. Add literature synthesis citations
3. Update validation receipts with combined status
